Cancer Biomarkers Market by Type (Genetic Biomarker, Protein Biomarker), Cancer Type (Leukemia, Lung, Breast, Melanoma), Application (Diagnosis, Prognostics, R&D), Profiling Technology (Immunoassay, Omics, Imaging, Bioinformatics) – 2019 to 2024

$3,850.00$5,850.00

AVAIL 20% DISCOUNT ON PURCHASE OF ANY REPORT
Published on: May 28, 2019
Clear
SKU: GMS1187 Category:

The size of the global market for cancer biomarkers is expected to grow during the forecast period at a CAGR of 11.7% to reach USD 21.7 billion by 2024. Major factors driving the market growth include rising cancer prevalence, advances in omics technology, increased healthcare spending, growth in government and private funding for R&D, and increased demand for personalized medicine in cancer therapy.

Cancer Biomarkers Market by Type (Genetic Biomarker, Protein Biomarker), Cancer Type (Leukemia, Lung, Breast, Melanoma), Application (Diagnosis, Prognostics, R&D), Profiling Technology (Immunoassay, Omics, Imaging, Bioinformatics) - 2019 to 2024 1

Cancer Biomarkers Market by Type (Genetic Biomarker, Protein Biomarker), Cancer Type (Leukemia, Lung, Breast, Melanoma), Application (Diagnosis, Prognostics, R&D), Profiling Technology (Immunoassay, Omics, Imaging, Bioinformatics) - 2019 to 2024 2

Cancer Biomarkers Market by Type (Genetic Biomarker, Protein Biomarker), Cancer Type (Leukemia, Lung, Breast, Melanoma), Application (Diagnosis, Prognostics, R&D), Profiling Technology (Immunoassay, Omics, Imaging, Bioinformatics) - 2019 to 2024 3

Cancer Biomarkers Market by Type (Genetic Biomarker, Protein Biomarker), Cancer Type (Leukemia, Lung, Breast, Melanoma), Application (Diagnosis, Prognostics, R&D), Profiling Technology (Immunoassay, Omics, Imaging, Bioinformatics) - 2019 to 2024 4

Cancer Biomarkers Market by Type (Genetic Biomarker, Protein Biomarker), Cancer Type (Leukemia, Lung, Breast, Melanoma), Application (Diagnosis, Prognostics, R&D), Profiling Technology (Immunoassay, Omics, Imaging, Bioinformatics) - 2019 to 2024 5

Cancer Biomarkers Market by Type (Genetic Biomarker, Protein Biomarker), Cancer Type (Leukemia, Lung, Breast, Melanoma), Application (Diagnosis, Prognostics, R&D), Profiling Technology (Immunoassay, Omics, Imaging, Bioinformatics) - 2019 to 2024 6

Cancer Biomarkers Market by Type (Genetic Biomarker, Protein Biomarker), Cancer Type (Leukemia, Lung, Breast, Melanoma), Application (Diagnosis, Prognostics, R&D), Profiling Technology (Immunoassay, Omics, Imaging, Bioinformatics) - 2019 to 2024 7

Cancer Biomarkers Market by Type (Genetic Biomarker, Protein Biomarker), Cancer Type (Leukemia, Lung, Breast, Melanoma), Application (Diagnosis, Prognostics, R&D), Profiling Technology (Immunoassay, Omics, Imaging, Bioinformatics) - 2019 to 2024 8

1 Global Cancer Biomarkers Market 
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 Global Cancer Biomarkers Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 Global Cancer Biomarkers Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis

5 Global Cancer Biomarkers Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies

6 Global Cancer Biomarkers Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes

7 Global Cancer Biomarkers Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)

8 Global Cancer Biomarkers Market – By Biomolecule (Market Size – & million/billion)
8.1 Protein Biomarkers
8.2 Genetic Biomarkers
8.3 Epigenetic Biomarkers
8.4 Metabolic Biomarkers
8.5 Other

9 Global Cancer Biomarkers Market – By Cancer Type
9.1 Breast Cancer
9.2 Lung Cancer
9.3 Prostate Cancer
9.4 Non-Hodgkin’s Lymphoma
9.5 Leukemia
9.6 Thyroid Cancer
9.7 Bladder Cancer
9.8 Kidney Cancer
9.9 Other

10 Global Cancer Biomarkers Market – By Application
10.1 Drug Discovery
10.2 Diagnostics
10.3 Personalized Medicine
10.4 Other

11 Global Cancer Biomarkers Market – By Geography (Market Size – & million/billion)
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 U.K
11.3.2 Germany
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 South Korea
11.4.5 Rest of APAC
11.5 Rest of the World
11.5.1 South America
11.5.2 Middle East
11.5.3 Africa

12 Global Cancer Biomarkers Market – Entropy
12.1 New product launches
12.2 M&A’s, collaborations, JVs and partnerships

13 Global Cancer Biomarkers Market Company Profile (Key Players)
13.1 Market Share, Company Revenue, Products, M&A, Developments
13.2 GE Healthcare
13.3 Agilent Technologies
13.4 Biomérieux SA
13.5 Thermo Fisher Scientific
13.6 Qiagen N.V.
13.7 Becton, Dickinson and Company
13.8 Danaher Corporation
13.9 Merck & Co.
13.10 Bio-Rad Laboratories
13.11 Myriad Genetics
13.12 Company 11 & more

14 Global Cancer Biomarkers Market – Appendix
14.1 Sources
14.2 Abbreviations